The endocannabinoid system is projected to grow at an annualized rate of ~30%, (till 2030)

Roots Analysis has done a detailed study on Endocannabinoid System Targeted Therapeutics Market, 2020-2030 “ covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 250+ page report, which features 140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html

Key Market Insights
 More than 65 industry players across the world are presently engaged in evaluating the clinical applications of over180 cannabinoid-derivatives that target the human endocannabinoid signaling system
 The pipeline features a variety of marketed / clinical stage therapies, being investigated for a wide range of target disease indications and designed for administration via different routes
 The geographical landscape of this industry is likely to evolve in the next few years as federal authorities legalize the use of medical cannabis across multiple countries
 Despite the associated stigma, many organizations have extended financial support to aid research efforts in this domain; the focus is on understanding the clinical benefits of endocannabinoid signaling in different diseases
 The growing interest in this field is also reflected by the 170+ partnerships that have been signed in the last five years, involving both international and indigenous stakeholders, across different geographical marketplaces
 Presently, North American companies seem to be consolidating their presence indigenously, mostly through strategic acquisitions; key value drivers behind such deals include product and geographical expansion
 Future market size, based on revenue generation potential of marketed and late stage therapies, is anticipated to be distributed across a variety of therapeutic areas, target receptors and key geographical regions

For more information, please visit “Endocannabinoid System Targeted Therapeutics Market, 2020-2030.“